

Human Papillomavirus Vaccines (HPV)

Vaccine	Protects against HPV types	FDA Approved for Protection Against	Approved for	Ages
HPV2 Cervarix® (GSK)	16 and 18	Cervical cancer	Females ONLY	Females: 9–26 years of age Males: 9-21 years See "Indications": males 22-26 years)
HPV4 Gardasil® (Merck)	6, 11, 16 and 18	Cervical, vulvar, vaginal, anal cancers; genital warts	Females & Males	
HPV9 Gardasil® (Merck)	6,11,16,18,31,33,45,52 and 58	Same as HPV4, plus precancerous or dysplastic lesions	Females & Males	

Whenever possible, the same HPV vaccine product should be used for all doses in the series

<p>Indications for Use and Schedule</p> <ul style="list-style-type: none"> Routinely administer to males & females aged 11-12 years Catch-up: females aged 13-26 years & males aged 13-21 years Vaccinate males aged 22-26 within a high risk group <ul style="list-style-type: none"> Immunocompromised due to infection (including HIV), disease or Medication Men having sex with men <p>Consider vaccination for all other males aged 22-26 years</p> <p>Recommended Schedule: 0, 1-2, 6 months</p> <ul style="list-style-type: none"> Use recommended schedule dosing intervals for series catch-up If minimum intervals are needed, make sure there are: <ul style="list-style-type: none"> 4 weeks between dose 1 & 2 12 weeks between dose 2 & 3 24 weeks between dose 1 & 3 	<p>Vaccine Administration</p> <ul style="list-style-type: none"> Intramuscular injection in the deltoid of the arm or anterolateral thigh <u>only</u> 1-1.5 inch needle; 22-25 gauge Use professional judgment when selecting needle length Can be given simultaneously with other vaccines
	<p>Storage and Handling</p> <ul style="list-style-type: none"> Store in the refrigerator between 35°-46° F (2°-8°C) Do NOT freeze Keep in the original box Shake well before use



SPECIAL SITUATIONS

Vaccine Schedule

- Series may be started at age 9-10 years at the provider's discretion. The best way to be sure that a person gets the most benefit from HPV is to complete all three doses before sexual activity begins. However, sexually active persons 9 through 26 years of age should also be vaccinated.
- Persons turning 27 years of age after the first dose of HPV was administered but before the third dose is given can complete the series using the recommended intervals between doses, even though this means that the series is completed after 26 years

Vaccine can be given to those with:

- Have Genital warts
- Are breastfeeding
- Are Immunosuppressed
- A positive HPV test
- An equivocal or abnormal Pap test
- Are currently taking hormonal contraceptive measures

Contraindications

Allergic reaction to a previous dose of HPV vaccine or another component of the vaccine

- HPV4 & HPV9 (Gardasil) is contraindicated for persons with a history of immediate hypersensitivity to yeast
- HPV2 (Cervarix) in prefilled syringes is contraindicated for persons with anaphylactic latex allergy

Precautions

Moderate or severe illness

Pregnancy

- Pregnancy testing is not needed before vaccination
- If a woman is pregnant after starting the vaccine series, remaining doses should be delayed until after the pregnancy
- If a vaccine dose has been administered during pregnancy, there is no indication for medical intervention
- Report vaccination of pregnant women to the HPV registry: **HPV9 (Gardasil): 800-986-8999**

Further Points

- If the HPV vaccine previously administered is unknown or not available, do not miss an opportunity; complete series with any appropriate brand; Females: HPV2/HPV4/HPV9 and Males: HPV4/HPV9. There is currently no current recommendation for revaccinating persons who previously received HPV2 or HPV4.
- Due to increased reports of syncope (fainting) in adolescents following vaccination, a 15-20 minute observation period is recommended for adolescents after receiving vaccines
- A separate Vaccine Information Statement (VIS) for Gardasil (HPV4), Gardasil (HPV 9) and Cervarix (HPV2). Use the VIS that matches the vaccine you are giving. All HPV VISs, can be found at <http://www.immunize.org/vis/>

For additional information, refer to *Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated Vaccination Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, March 27, 2015. Found at <http://cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm>*